Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 16;29(5):3576-3584.
doi: 10.3390/curroncol29050289.

The Role of Microorganisms in Appendiceal Pseudomyxoma Peritonei: A Review

Affiliations
Review

The Role of Microorganisms in Appendiceal Pseudomyxoma Peritonei: A Review

Yekaterina Khamzina et al. Curr Oncol. .

Abstract

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome. It originates from neoplasms of the appendix and leads to the formation of peritoneal implants and the accumulation of mucinous ascites. PMP represents a spectrum of low to high-grade disease. Despite aggressive management, many PMP patients recur, leading to debilitating symptoms and few treatment options. Therefore, scientists have continued to look for ways to improve treatment and further understand disease pathogenesis. Microorganisms were previously hypothesized to play a role in PMP progression and development. Hence, antibacterial treatment was suggested by some authors, but the data were limited. In this paper, we review the current data on the role of bacteria in PMP, discuss the significance, and suggest possible solutions to the inherent challenges in these studies. Given the limitations of the discussed studies, we remain skeptical about introducing novel antibacterial treatment into clinical practice at this time; however, the available data are valuable and indicate that more research into the molecular mechanisms of PMP is needed.

Keywords: Helicobacter pylori; antibacterial treatment; appendiceal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Patrick-Brown T., Carr N.J., Swanson D.M., Larsen S., Mohamed F., Flatmark K. Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Ann. Surg. Oncol. 2021;28:252–257. doi: 10.1245/s10434-020-08655-8. - DOI - PMC - PubMed
    1. Carr N.J., Bibeau F., Bradley R.F., Dartigues P., Feakins R.M., Geisinger K.R., Gui X., Isaac S., Milione M., Misdraji J., et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71:847–858. doi: 10.1111/his.13324. - DOI - PubMed
    1. Semino-Mora C., Testerman T.L., Liu H., Whitmire J.M., Studeman K., Jia Y., McAvoy T.J., Francis J., Nieroda C., Sardi A., et al. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects beta-catenin distribution. Clin. Cancer Res. 2013;19:3966–3976. doi: 10.1158/1078-0432.CCR-13-0616. - DOI - PubMed
    1. Smeenk R.M., van Velthuysen M.L., Verwaal V.J., Zoetmulder F.A.N. Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. Eur. J. Surg. Oncol. 2008;34:196–201. doi: 10.1016/j.ejso.2007.04.002. - DOI - PubMed
    1. Bevan K.E., Mohamed F., Moran B.J. Pseudomyxoma peritonei. World J. Gastrointest. Oncol. 2010;2:44–50. doi: 10.4251/wjgo.v2.i1.44. - DOI - PMC - PubMed

MeSH terms